These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 24336058)
21. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials. Nicholls TR; Leach AJ; Morris PS Vaccine; 2016 Feb; 34(6):703-13. PubMed ID: 26742947 [TBL] [Abstract][Full Text] [Related]
22. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination? Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Jayasinghe S; Chiu C; Quinn H; Menzies R; Gilmour R; McIntyre P Clin Infect Dis; 2018 Jul; 67(3):367-374. PubMed ID: 29471432 [TBL] [Abstract][Full Text] [Related]
25. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921 [TBL] [Abstract][Full Text] [Related]
26. Pneumococcal conjugate vaccine failure in children: A systematic review of the literature. Oligbu G; Hsia Y; Folgori L; Collins S; Ladhani S Vaccine; 2016 Dec; 34(50):6126-6132. PubMed ID: 27838066 [TBL] [Abstract][Full Text] [Related]
28. The impact of a pneumococcal conjugate vaccination program on the nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among healthy children in Turkey. Soysal A; Karabağ-Yılmaz E; Kepenekli E; Karaaslan A; Cagan E; Atıcı S; Atınkanat-Gelmez G; Boran P; Merdan S; Hasdemir U; Söyletir G; Bakır M Vaccine; 2016 Jul; 34(33):3894-900. PubMed ID: 27269059 [TBL] [Abstract][Full Text] [Related]
29. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. Madhi SA; Cohen C; von Gottberg A Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016 [TBL] [Abstract][Full Text] [Related]
30. Acquisition of Streptococcus pneumoniae in South African children vaccinated with 7-valent pneumococcal conjugate vaccine at 6, 14 and 40 weeks of age. Nunes MC; Jones SA; Groome MJ; Kuwanda L; Van Niekerk N; von Gottberg A; de Gouveia L; Adrian PV; Madhi SA Vaccine; 2015 Jan; 33(5):628-34. PubMed ID: 25541213 [TBL] [Abstract][Full Text] [Related]
31. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Nuorti JP; Whitney CG; MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868 [TBL] [Abstract][Full Text] [Related]
32. Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya. Flasche S; Ojal J; Le Polain de Waroux O; Otiende M; O'Brien KL; Kiti M; Nokes DJ; Edmunds WJ; Scott JAG BMC Med; 2017 Jun; 15(1):113. PubMed ID: 28592303 [TBL] [Abstract][Full Text] [Related]
33. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717 [TBL] [Abstract][Full Text] [Related]
34. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB; Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233 [TBL] [Abstract][Full Text] [Related]
36. Methods for a systematic review of pneumococcal conjugate vaccine dosing schedules. Loo JD; Conklin L; Deloria Knoll M; Fleming-Dutra KE; Park DE; Kirk J; Johnson TS; Goldblatt D; O'Brien KL; Whitney CG Pediatr Infect Dis J; 2014 Jan; 33 Suppl 2(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supportin g Different Schedules):S182-7. PubMed ID: 24336060 [TBL] [Abstract][Full Text] [Related]
37. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study. Chan J; Gidding HF; Blyth CC; Fathima P; Jayasinghe S; McIntyre PB; Moore HC; Mulholland K; Nguyen CD; Andrews R; Russell FM PLoS Med; 2021 Aug; 18(8):e1003733. PubMed ID: 34343186 [TBL] [Abstract][Full Text] [Related]
38. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Scott P; Rutjes AW; Bermetz L; Robert N; Scott S; Lourenço T; Egger M; Low N Vaccine; 2011 Dec; 29(52):9711-21. PubMed ID: 21821080 [TBL] [Abstract][Full Text] [Related]
39. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance. ; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357 [TBL] [Abstract][Full Text] [Related]
40. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Dagan R; Givon-Lavi N; Porat N; Greenberg D Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]